Sevoflurane inhibits unstimulated and agonist-induced platelet antigen expression and platelet function in whole blood In Vitro

Anesthesiology

Volumn 95, Issue 5, 2001, Pages 1220-1225

  Horn, Nicola A ^a,c   De Rossi, Lothar ^a   Robitzsch, Tilo ^b   Hecker, Klaus E ^a   Hutschenreuter, Gabriele ^b   Rossaint, Rolf ^a  

^a Department of Anesthesiology ^*  (Germany)

^b Institute of Transfusion Medicine

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; FIBRINOGEN RECEPTOR; GLYCOPROTEIN IB; PADGEM PROTEIN; SEVOFLURANE; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBOCYTE ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; MINIMUM LUNG ALVEOLUS CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

EID: 0034767210     PISSN: 00033022     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000542-200111000-00028     Document Type: Article

References (25)

1. The effects of volatile general anesthetics on adenosine diphosphate-induced platelet aggregation
2. Sevoflurane inhibits human platelet aggregation and thromboxane A2 formation, possibly by suppression of cyclooxygenase activity
3. Platelet aggregation is impaired during anaesthesia with sevoflurane but not with isoflurane
4. Influence of volatile anesthetics on thromboxane A2 signaling
5. The in vitro effects of isoflurane, sevoflitrane, and propofol on platelet aggregation
6. Sevoflurane does not inhibit human platelet aggregation induced by thrombin
7. Platelet adhesion and thrombus formation on subendothelium in platelets deficient in glycoproteins IIb-IIIa, Ib, and storage granules
8. European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function
9. Platelet GPIb-V-IX complex: Structure, function, physiology, and pathology
10. Expression of ligand-induced binding sites on glycoprotein IIb/IIIa complexes and the effect of various inhibitors
11. Description of an in vitro platelet function analyzer: PFA-100
12. Methods for monitoring platelet function
13. Use of abciximab-modified thrombelastography in patients undergoing cardiac surgery
14. Assessing platelet and fibrinogen contribution to clot strength using modified thromboelastography in pregnant women
15. Changes in glycoprotein expression after platelet activation: Differences between in vitro and in vivo studies
16. Thrombin induces a rapid redistribution of glycoprotein Ib-IX complexes within the membrane systems of activated human platelets
17. Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or an in vivo wound
18. The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible
19. Volatile anaesthetics induce changes in the expression of P-selectin and glycoprotein lb on the surface of platelets in vitro
20. Platelet-leukocyte interactions
21. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa Ilb-Illa receptor blockade by abciximab: Importance of internal pool of glycoprotein IIb-IIIa receptors
22. Signaling through platelet integrin alpha IIb beta 3: Inside-out, outside-in, and sideways
23. Role of intracellular signaling events in ADP-induced platelet aggregation
24. Direct inhibitory mechanisms of halothane on human platelet aggregation
25. Comparison of sevoflurane and propofol for ambulatory anaesthesia in gynaecological surgery